Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paricalcitol - Abbvie

Drug Profile

Paricalcitol - Abbvie

Alternative Names: 19-Nor-1-25-OH2D2; 19-Nor-colecalciferol; Paracalcin; Zemplar; Zemplar Capsules

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Cedars-Sinai Medical Center
  • Class Antineoplastics; Ergocalciferols; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Secondary hyperparathyroidism
  • Phase II Myelodysplastic syndromes

Most Recent Events

  • 22 Aug 2019 AbbVie plans a phase III trial for Secondary hyperparathyroidism (In Infants, In children, In neonates) in USA and Puerto Rico in December 2019(NCT04064827)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Apr 2015 AbbVie completes a phase III trial in Secondary hyperparathyroidism in Germany, USA and Portugal (NCT01382212)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top